- Home
- ALEC vs MSLE Comparison
ALEC vs MSLE Comparison
Compare ALEC & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALEC | MSLE |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | Canada |
| Employees | 103 | 21 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.8M | 154.6M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALEC | MSLE |
|---|---|---|
| Price | $1.54 | $8.53 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.83 | N/A |
| AVG Volume (30 Days) | ★ 879.4K | 77.0K |
| Earning Date | 05-04-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,045,000.00 | N/A |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $29.87 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $5.44 |
| 52 Week High | $3.40 | $13.39 |
Technical Indicators
Market Signals| Indicator | ALEC | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 40.32 | 56.41 |
| Support Level | $1.37 | $6.71 |
| Resistance Level | $1.60 | $8.59 |
| Average True Range (ATR) | 0.14 | 0.75 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 18.71 | 46.29 |
Price Performance
Historical ComparisonAbout ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.